Items in cart [1] Questions? Call 888-624-8373

Rights & Permissions Free PDF Access Free Resources Sign in to download PDF book and chapters Display this book on your site! Related Titles Saving Lives, Buying Time: Economics of Malaria Drugs in an Age of Resistance Ensuring an Infectious Disease Workforce: Education and Training Needs for the 21st Century - Workshop Summary Other Related Titles Assessment of the Role of Intermittent Preventive Treatment for Malaria in Infants: Letter Report (2008) Board on Global Health (BGH) Web Search Builder Use this book's key terms to search within this book, across our collection, or across the Web. Skim This Chapter Skim this chapter and use this chapter's key terms to search within this book. Reference Finder Paste in your own text to find books that relate to your topic. Page 80   E-mail  Facebook  Digg  Stumble  Twitter More The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy. Appendix F List of Tables, Figures, and Boxes TABLES Table 1   World Health Organization—Recommended EPI Schedule,   8 Table 2   Characteristics of the Six IPTi-SP Trials,   18 Table 3   Primary Outcome and Power of the Six IPTi-SP Trials,   21 Table 4   Summary of Outcomes of the Six IPTi-SP Studies and the Kisumu Trial During the First Year of Life,   22 Table 5   Summary of Outcomes of the Six IPTi-SP Trials Through 12 Months of Age,   25 Table 6   Mortality in the First Year of Life for the Six IPTi-SP Trials,   26 Table 7   Effect of SP During Treatment Period, Rebound Period, and Time from Randomization to End of Follow-Up,   29 Table 8   Incidence of Malaria During Prophylactic Effect 1 (Period of 35 Days After Dose at 3 Months),   30 Table 9   Incidence of Malaria During Prophylactic Effect 2 (Period of 35 Days After Dose at 9 Months),   30 Table 10   Incidence of Malaria During the Inter-Dose 1 Period,   32 Table 11   Protective Efficacy (PE) and Reported 95% Confidence Intervals (CI) for Outcomes During the 5 Months After Last Dose of SP or Placebo,   35 Table 12   Incidence of Malaria from Randomization up to 5 Months After the Last Dose of SP,   36 Table 13   Risk of Anemia from Randomization Up to 5 Months After the Last Dose of SP,   36 Table 14   Incidence of Hospital Admission with Malaria Parasites from Randomization Up to 5 Months After the Last Dose of SP,   37 Table 15   Incidence of All-Cause Hospital Admissions from Randomization Up to 5 Months After the Last Dose of SP,   37 Table 16   Protective efficacy (PE) and Reported 95% Confidence Intervals (CI) for Outcomes During the 11 Months After Last Dose of SP or Placebo,   39 Table 17   Protective Efficacy (PE) and Reported 95% Confidence Intervals (CI) for Outcomes from Randomization Through 11 Months After Last Dose of SP or Placebo,   40 Table 18   Overall Pooled Estimates of Efficacy Against Clinical Malaria and Other Relevant Outcomes During Two Periods of Follow-Up,   43 Table 19   Safety Monitoring for IPTi Surveillance Methods of the Six IPTi-SP Studies and the Kisumu Trial,   48 FIGURES Figure 1   Incidence of first clinical malaria episodes over the course of the malaria season among subjects who received curative sulfadoxine-pyrimethamine,   13 BOXES Box 1   A Summary of the Methods Used in Each IPTi-SP Study to Detect Critical Outcomes Including Clinical Malaria and (Depending on the Specific Study) Anemia, Hospitalization of Patients with Malaria Parasites, and All Cause Hospitalizations,   15 Box 2   List of Committee Findings and Conclusions by Order of Appearance in the Letter Report,   59 Box 3   Committee Recommendations in Order of Significance,   63 Page 80 Letter Report (1-64) Appendix A Committee Members and Staff (65-65) Appendix B References (66-73) Appendix C Glossary (74-75) Appendix D Meeting Agenda (76-78) Appendix E Reviewers (79-79) Appendix F List of Tables, Figures, and Boxes (80-80)

Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.

OCR for page 80
Assessment of the Role of Intermittent Preventive Treatment for Malaria in Infants: Letter Report Appendix F List of Tables, Figures, and Boxes TABLES Table 1   World Health Organization—Recommended EPI Schedule,   8 Table 2   Characteristics of the Six IPTi-SP Trials,   18 Table 3   Primary Outcome and Power of the Six IPTi-SP Trials,   21 Table 4   Summary of Outcomes of the Six IPTi-SP Studies and the Kisumu Trial During the First Year of Life,   22 Table 5   Summary of Outcomes of the Six IPTi-SP Trials Through 12 Months of Age,   25 Table 6   Mortality in the First Year of Life for the Six IPTi-SP Trials,   26 Table 7   Effect of SP During Treatment Period, Rebound Period, and Time from Randomization to End of Follow-Up,   29 Table 8   Incidence of Malaria During Prophylactic Effect 1 (Period of 35 Days After Dose at 3 Months),   30 Table 9   Incidence of Malaria During Prophylactic Effect 2 (Period of 35 Days After Dose at 9 Months),   30 Table 10   Incidence of Malaria During the Inter-Dose 1 Period,   32 Table 11   Protective Efficacy (PE) and Reported 95% Confidence Intervals (CI) for Outcomes During the 5 Months After Last Dose of SP or Placebo,   35 Table 12   Incidence of Malaria from Randomization up to 5 Months After the Last Dose of SP,   36 Table 13   Risk of Anemia from Randomization Up to 5 Months After the Last Dose of SP,   36 Table 14   Incidence of Hospital Admission with Malaria Parasites from Randomization Up to 5 Months After the Last Dose of SP,   37 Table 15   Incidence of All-Cause Hospital Admissions from Randomization Up to 5 Months After the Last Dose of SP,   37 Table 16   Protective efficacy (PE) and Reported 95% Confidence Intervals (CI) for Outcomes During the 11 Months After Last Dose of SP or Placebo,   39 Table 17   Protective Efficacy (PE) and Reported 95% Confidence Intervals (CI) for Outcomes from Randomization Through 11 Months After Last Dose of SP or Placebo,   40 Table 18   Overall Pooled Estimates of Efficacy Against Clinical Malaria and Other Relevant Outcomes During Two Periods of Follow-Up,   43 Table 19   Safety Monitoring for IPTi Surveillance Methods of the Six IPTi-SP Studies and the Kisumu Trial,   48 FIGURES Figure 1   Incidence of first clinical malaria episodes over the course of the malaria season among subjects who received curative sulfadoxine-pyrimethamine,   13 BOXES Box 1   A Summary of the Methods Used in Each IPTi-SP Study to Detect Critical Outcomes Including Clinical Malaria and (Depending on the Specific Study) Anemia, Hospitalization of Patients with Malaria Parasites, and All Cause Hospitalizations,   15 Box 2   List of Committee Findings and Conclusions by Order of Appearance in the Letter Report,   59 Box 3   Committee Recommendations in Order of Significance,   63